EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico

Juan Pablo Diaz Martinez iD, Therese Aubry de Maraumont, Elly Natty Sánchez, Luis Miguel Camacho Cordero, Eric Yeh

PLOS ONE · 07.02.2025 · 20 (2) · e0299673

DOI: 10.1371/journal.pone.0299673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 07.02.2025. Verfasst von Juan Pablo Diaz Martinez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Antibodies, Monoclonal, Bone Density Conservation Agents, Fractures, Bone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Mexico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women.

Methods

A Markov model was used to assess the relative cost effectiveness of 1 year of romosozumab versus 2 years of teriparatide, both sequenced to denosumab for a total treatment duration of 5 years. Outcomes for a cohort of women with a mean age of 74 years, a T-score ≤-2.5 and a previous fragility fracture were simulated over a lifetime horizon. The analysis was conducted from the perspective of the Mexican healthcare system and used a discount rate of 5% per annum. To inform relative fracture incidence, the bone mineral density (BMD) advantage of romosozumab over teriparatide was translated into relative risks of fracture, using relationships provided by a meta-regression of osteoporosis therapy trials. Outcomes were assessed in terms of lifetime costs (2023 Mexican pesos), quality-adjusted life years (QALYs) and life-years gained (LYs).

Results

Base case results showed that, compared with teriparatide/ denosumab, romosozumab/ denosumab reduced costs by $51,363 MXN per patient and yielded 0.03 additional QALYs and 0.01 LYs. Scenario analyses and probabilistic sensitivity analyses confirmed that results are robust to uncertainty in model assumptions and inputs.

Conclusions

Results show that romosozumab/ denosumab produces greater health benefits at a lower total cost than teriparatide/ denosumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporosis, PostmenopausalAntibodies, MonoclonalBone Density Conservation AgentsFractures, BoneOsteoporotic FracturesHumansFemaleMexicoCost-Benefit AnalysisAgedTeriparatideMarkov ChainsBone DensityDenosumabQuality-Adjusted Life YearsMiddle AgedAged, 80 and overCost-Effectiveness Analysis

Substanzen

romosozumabAntibodies, MonoclonalTeriparatideBone Density Conservation AgentsDenosumab

Autor:innen und Institutionen

  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
  • Health Economics Amgen Mexico, Mexico City, Mexico.
  • Health Economics Amgen, Thousand Oaks, CA, United States of America.

ORCID-Profile: Juan Pablo Diaz Martinez

Förderung

  • Amgen Mexico

Zitieren

APA

Diaz Martinez, J. P., Aubry de Maraumont, T., Natty Sánchez, E., Camacho Cordero, L. M., & Yeh, E. (2025). Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico. PLOS ONE, 20(2), e0299673. https://doi.org/10.1371/journal.pone.0299673

Vancouver

Diaz Martinez JP, Aubry de Maraumont T, Natty Sánchez E, Camacho Cordero LM, Yeh E. Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico. PLOS ONE. 2025;20(2):e0299673. doi:10.1371/journal.pone.0299673

BibTeX
@article{DiazMartinez2025,
  author = {Diaz Martinez, Juan Pablo and Aubry de Maraumont, Therese and Natty Sánchez, Elly and Camacho Cordero, Luis Miguel and Yeh, Eric},
  title = {Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {2},
  pages = {e0299673},
  doi = {10.1371/journal.pone.0299673}
}
Kostenlos starten →